Syra Health (SYRA) investor relations material

Company overview and business model

• Provides integrated healthcare solutions focused on prevention, access, and affordability, serving government and commercial clients across behavioral and mental health, population health, digital health, health education, and workforce development.

• Offers proprietary digital products such as Syrenity, an AI-driven mental health app, and digital health platforms including chatbots and EMR solutions.

• Delivers services to payers, providers, life sciences, academic institutions, and government agencies, with a strong emphasis on data analytics and health equity.

• Growth strategy includes expanding geographically, investing in partnerships, and potential acquisitions to enhance service lines and market reach.

Financial performance and metrics

• Generated $7.2M in revenue in 2025 and $8.0M in 2024; $4.7M for the six months ended June 30, 2026.

• Net loss decreased from $3.76M in 2024 to $896K in 2025; net income of $491K for the six months ended June 30, 2026.

• Gross profit margin improved from 21% in 2024 to 34% in 2025 and 44% for the first half of 2026.

• Cash balance was $2.12M as of June 30, 2026, with an accumulated deficit of $9.23M.

• Significant customer concentration: FSSA and Humana accounted for a large portion of revenues and receivables.

Use of proceeds and capital allocation

• Will not receive proceeds from stockholder sales; may receive up to $2.03M if all Series B Warrants are exercised for cash.

• Proceeds from warrant exercises intended for marketing, sales, application development, R&D, general corporate purposes, and potential acquisitions.

• Management retains broad discretion over allocation of proceeds.